Expert's Area Login
The Expert's Area is accessable
through your DocCheck Login.
If you have none yet, apply here.
Frankfurt am Main, 31.07.2013
Merz Pharma Group (Frankfurt am Main) today announced that it has acquired the Swiss pharmaceutical company Neocutis S.A. The acquisition of the company`s cosmeceutical skin care business strengthens Merz`s market position in the field of aesthetic dermatology.
Castres, Frankfurt am Main, 06.09.2012
In accordance with the announcement made on May 9th, pharmaceuticals laboratories Pierre Fabre (France) and Merz Pharmaceuticals (Germany) have signed a partnership agreement on the marketing of Glytone® products. Under this agreement, Merz Group acquires the Glytone® range of injectable hyaluronic acid products used to fill wrinkles, as well as several accompanying dermo-cosmetic products. Merz becomes owner of the global rights to Glytone® injectable hyaluronic acid products and the non-US rights to the other products of the brand.
Castres, Frankfurt am Main, 14.05.2012
Pierre Fabre (France) and Merz Pharmaceuticals (Germany) today announced the kick-off of exclusive negotiations to collaborate in aesthetics. Initially, Merz intends to acquire Glytone’s® fillers, a unique family of hyaluronic acid injectables to reduce wrinkles and their accompanying dermo-cosmetic products.
Frankfurt am Main, 19.03.2012
The Merz Pharma Group today confirmed that its two US subsidiaries Merz Aesthetics Inc. and Merz Pharmaceuticals LLC will for now not be allowed to market Xeomin or its dermal fillers in the U.S. market without restrictions.